Shares in Intersect ENT (NSDQ:XENT) surged today after the drug-device company beat expectations on Wall Street with its second quarter results.
The Menlo Park, Calif.-based company posted a loss of -$2.3 million on sales of $24 million for the 3 months ended June 30, for bottom-line growth of 62% on sales growth of 24% compared with the same period last year.
Get the full story at our sister site, Drug Delivery Business News.
The post Intersect ENT tops EPS, sales estimates in Q2 appeared first on MassDevice.
from MassDevice http://ift.tt/2wlpigD
Cap comentari:
Publica un comentari a l'entrada